Onyeaka Helen, Tamasiga Phemelo, Agbara Joy O, Mokgwathi Oreneile Anikie, Uwishema Olivier
School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Am Depenbrock, Gütersloh, Germany.
Clin Epidemiol Glob Health. 2022 Jul-Aug;16:101074. doi: 10.1016/j.cegh.2022.101074. Epub 2022 Jun 8.
The outbreak of SARS-CoV-2 pandemic has triggered unprecedented social, economic and health challenges. To control and reduce the infection rate, countries employed non-pharmaceutical measures such as social distancing, isolation, quarantine, and the use of masks, hand and surface sanitisation. Since 2021 a global race for COVID-19 vaccination ensued, mainly due to a lack of equitable vaccine production and distribution. To date, no treatments have been demonstrated to cure COVID-19. The scientific World is now considering the potential use of Ivermectin as a prophylactic and treatment for COVID-19. Against this background, the objective of this study is to review the literature to demystify the enigma or panacea in the use of Ivermectin. This paper intends to investigate literature which supports the existence or shows the nonexistence of a causal link between Ivermectin, COVID-19 mortality and recovery. There are inconsistent results on the effectiveness of Ivermectin in the treatment of COVID-19 patients. Some studies have asserted that in a bid to slow down the transmission of COVID-19, ivermectin can be used to inhibit the in vitro replication of SARS-CoV-2. The pre-existing health system burdens can be alleviated as patients treated prophylactically would reduce hospital admissions and stem the spread of COVID-19. On a global scale, Ivermectin is currently used by about 28% of the world's population, and its adoption is presently about 44% of countries. However, the full administration of this drug would require further tests to establish its clinical effectiveness and efficacy.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行的爆发引发了前所未有的社会、经济和健康挑战。为了控制和降低感染率，各国采取了诸如保持社交距离、隔离、检疫以及使用口罩、手部和表面消毒等非药物措施。自2021年以来，全球展开了一场针对新冠病毒疫苗接种的竞赛，主要原因是缺乏公平的疫苗生产和分配。迄今为止，尚无治疗方法被证明能治愈新冠病毒疾病（COVID-19）。科学界目前正在考虑将伊维菌素作为COVID-19的预防和治疗药物的潜在用途。在此背景下，本研究的目的是回顾文献，揭开伊维菌素使用中的谜团或万灵药的真相。本文旨在调查支持伊维菌素与COVID-19死亡率和康复之间存在因果关系或表明不存在因果关系的文献。关于伊维菌素治疗COVID-19患者的有效性存在不一致的结果。一些研究断言，为了减缓COVID-19的传播，伊维菌素可用于抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的体外复制。由于预防性治疗的患者将减少住院人数并遏制COVID-19的传播，因此可以减轻现有的卫生系统负担。在全球范围内，目前约28%的世界人口使用伊维菌素，目前约44%的国家采用了该药物。然而，要全面使用这种药物还需要进一步测试以确定其临床有效性和疗效。
